Company Sponsored Symposia

Thursday, 30 April 2015


Time
HALL A - Plenary Room
“Terpsichore A&B” 
13.00 - 14.00 Lunch Company Sponsored Symposium I:
RANK Ligand inhibition in skeletal oncology
 Sponsored by:
 


Chair: Thomas Brodowicz, Austria

13.00–13.05   Welcome and introduction | Thomas Brodowicz, Austria
13.05–13.20   Targeting cancer-related bone disease with RANK Ligand inhibition | Thomas Brodowicz, Austria
13.20–13.35   Pain, quality of life and the bone | Athina Vadalouka, Greece
13.35–13.50   Advancing treatment options in giant cell tumour of bone | Javier Martin-Broto, Spain
13.50–14.00   Q&A

Time
HALL A - Plenary Room
“Terpsichore A&B” 
14.00 - 15.00 Company Sponsored Symposium II:
 Sponsored by:

ADVANCED SOFT-TISSUE SARCOMA - THE CHALLENGE OF A RARE HETEROGENEOUS DISEASE:
Evidence Guided Treatment Decisions


Welcome and introduction | Stefan Sleijfer
Current treatment landscape in aSTS
| Stefan Sleijfer
The role of clinical trials in advancing treatment for aSTS | Patrick Schöffski
Moving into everyday clinical practice: experience outside of the clinical trial setting | Hans Gelderblom
Panel discussion and Q&A | ALL
Summary & meeting close
| Stefan Sleijfer

Faculty:
Professor Stefan Sleijfer, MD, PhD
Professor of Medical Oncology, Erasmus MC-Cancer Institute, Rotterdam, The Netherlands

Professor Patrick Schöffski, MPH
Head, Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven
Full professor, Faculty of Medicine, Department of Oncology, Head,
Research Unit Laboratory of Experimental,  Oncology, KU Leuven, Belgium

Professor Hans Gelderblom
Professor of Clinical Oncology
Leiden University Medical Center, Leiden, The Netherlands

Time
HALL A - Plenary Room
“Terpsichore A&B” 
15.00 - 16.00 Company Sponsored Symposium III:
 Sponsored by:


Chair: P.J.Papagelopoulos, Athens University Greece

15.00 - 15.04 Introduction | P.J. Papagelopoulos, Athens University, Greece
15:04 - 15.12 Endoprostheses around the Knee | Michaël Bus, LUMC, University of Leiden, The Netherlands
15.12 - 15.20 Treatment of periprosthetic fractures with MUTARS® |Prof. Jendrik Hardes, MS, University Muenster, Germany
15.20 - 15.28 Treatment options in periprosthetic infection of MUTARS Tumor Prosthesis |Dr. Burkhard Lehner, University of Heidelberg, Germany
15.28 - 15.36 Infected Megaprostheses | Dr. Vassilios Sakellariou, Athens University, Greece
15.36 - 15.44 New Technologies in reconstruction of bone defects in children and youth with primary malignant bone tumors - own experiences | Dr. Andrzej Szafrański, University Hospital Warszawa, Poland
15:44 - 15.52 Anatomical and biomechanical aspects of LUMIC prosthesis implantation in the sacrum |Dr. Daniel Kotrych, University Hospital Szczecin, Poland
15.52 - 16.00 Discussion